Mineralys Therapeutics (MLYS) Expected to Announce Earnings on Wednesday

Mineralys Therapeutics (NASDAQ:MLYS) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 12th. Analysts expect Mineralys Therapeutics to post earnings of ($1.00) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the previous year, the business earned ($0.57) earnings per share. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Stock Down 3.1 %

MLYS opened at $9.51 on Tuesday. Mineralys Therapeutics has a fifty-two week low of $8.58 and a fifty-two week high of $16.91. The business has a 50-day moving average of $11.39 and a 200-day moving average of $12.09.

Insider Transactions at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares of the company’s stock, valued at $2,057,482.70. The trade was a 4.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jon Congleton sold 18,333 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.06, for a total value of $166,096.98. Following the completion of the sale, the chief executive officer now directly owns 877,608 shares in the company, valued at approximately $7,951,128.48. This represents a 2.05 % decrease in their position. The disclosure for this sale can be found here. 33.24% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday, November 12th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.